000			04459nam a22004455i 4500
999			_c330528 _d330528 _x1
001			330528
003			ES-MaUEC
005			20230102114553.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			210223s2021 gw a s |||| 0|eng d
020			_a9783030685102
024	7		_a10.1007/978-3-030-68510-2 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _erda _dES-MaUEC
050		4	_aRB25 _b2021 EB
245	0	0	_aReactive Oxygen Species : _bNetwork Pharmacology and Therapeutic Applications _cedited by Harald H. H. W. Schmidt, Pietro Ghezzi, Antonio Cuadrado.
250			_aFirst edition 2021
264		1	_aCham _bSpringer International Publishing _c2021
300			_a1 recurso en línea (VIII, 425 páginas) _b70 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_aarchivo de trexto _bPDF _2rda
490	0		_aHandbook of Experimental Pharmacology _x0171-2004 _v264
490	0		_aBiomedical and Life Sciences (SpringerNature-11642)
490	0		_aBiomedical and Life Sciences (R0) (SpringerNature-43708)
505	0		_aPart I: ROS Revisited: Changing the Focus from Oxidative Stress and Redox Biology to Redox Medicine -- Demystifying oxidative stress -- Oxidants in Physiological Processes -- Network Medicine-Based Unbiased Disease Modules for Drug and Diagnostic Target Identification in ROSopathies -- Part II Targeting antioxidant responses -- Development of Telintra as an Inhibitor of Glutathione S-Transferase P -- Perspectives on the Clinical Development of NRF2-Targeting Drugs -- Part III: Inhibiting ROS formation and toxification -- NOX Inhibitors: From Bench to Naxibs to Bedside -- Nitric Oxide Synthase Inhibitors into the Clinic at Last -- Xanthine Oxidoreductase Inhibitors -- Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches -- Inhibition of Myeloperoxidase -- Part IV: Stimulating/substituting ROS -- Effects of Mammalian Thioredoxin Reductase Inhibitors -- Cardiovascular Therapeutic Potential of the Redox Siblings, Nitric Oxide (NO•) and Nitroxyl (HNO), in the Setting of Reactive Oxygen Species Dysregulation -- Tetrahydrobiopterin and Nitric Oxide Synthase Recouplers -- Part V: Repairing ROS damage -- Soluble Guanylate Cyclase Stimulators and Activators - Peter Sander -- Inhibitors of Advanced Glycation End Product (AGE) Formation and Accumulation.
520	3		_aReactive oxygen species (ROS) have been implicated in almost every human disease phenotype, without much, if any, therapeutic consequence foremost exemplified by the failure of the so-called anti-oxidants. This book is a game changer for the field and many clinical areas such as cardiology and neurology. The term 'oxidative stress' is abandoned and replaced with a systems medicine and network pharmacology-based mechanistic approach to disease. The ROS-related drugs discussed here target either ROS- forming or ROS -modifying enzymes for which there is strong clinical evidence. In addition, ROS targets are included as they jointly participate in causal mechanisms of disease. This approach is transforming the ROS field and represents a breakthrough in redox medicine indicating a path to patient benefit. In the coming years more targets and drugs may be discovered, but the approach will remain the same and this book will thus become, and for many years remain, the leading reference for ROSopathies and their treatment by network pharmacology. Chapter "Soluble Guanylate Cyclase Stimulators and Activators" is available open access under a Creative Commons Attribution 4.0 International License via link.springer.com.
988			_aSpringer_BiomedLife_2021
650		7	_2embne _aPatología _9138489
700	1		_aSchmidt, Harald H. H. W _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aGhezzi, Pietro _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aCuadrado, Antonio _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9783030685096
776	0	8	_iPrinted edition: _z9783030685119
776	0	8	_iPrinted edition: _z9783030685126
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-68510-2 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE _n0
998			_b04/2021 _dz _ek _zSI